TODAY'S PAPER
70° Good Evening
70° Good Evening
Business

Competing generic pressures Hi Tech Pharma shares

Hi-Tech Pharmacal employees at the Amityville plant in

Hi-Tech Pharmacal employees at the Amityville plant in 2010. Photo Credit: Tom Decker, 2010

Amityville-based Hi-Tech Pharmacal Co. Inc.'s share price fell sharply by mid-day Tuesday, by more than 15 percent, after news that a Mumbai, India, firm had received approval for a competing generic version of the rhinitis drug Flonase.

Hi-Tech shares by noon Tuesday had fallen to $35.50, down $6.34. Sales of its generic version of the corticosteroid nasal spray, fluticasone propionate, have played a big role in the company's recent success.

The Indian firm, Wockhardt, disclosed Tuesday that its generic version of the rhinitis spray had received approval from the U.S. Food and Drug Administration.

Wockhardt will immediately launch U.S. sales of the generic, fluticasone.


 

Comments

We're revamping our Comments section. Learn more and share your input.

More news